Princeton, NJ-based Hengrui Therapeutics, Inc. (HTI) is a U.S. biopharmaceutical company dedicated to developing and commercializing innovative drugs to address unmet medical needs. HTI’s current therapeutic areas of focus are oncology and endocrinology, with multiple clinical-stage assets for oncology/immuno-oncology and diabetes/weight loss in the pipeline.
See our Cookie Privacy Policy Here
